Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis

Molecular Psychiatry

Volumn 16, Issue 5, 2011, Pages 569-581

  Albaugh, V L ^a   Judson, J G ^a   She, P ^a   Lang, C H ^a   Maresca, K P ^b   Joyal, J L ^b   Lynch, C J ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b A Subsidiary of Lantheus Holdings   (United States)

Author keywords

atypical antipsychotics; free fatty acid uptake; hyperinsulinemiceuglycemic clamp; insulin resistance; lipogenesis; nutrient partitioning

Indexed keywords

FATTY ACID; GLUCOSE; INSULIN; ISOPRENALINE; OLANZAPINE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BODY FAT; CONTROLLED STUDY; DRUG DOSE INCREASE; ENERGY EXPENDITURE; FATTY ACID BLOOD LEVEL; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; IMPAIRED INSULIN TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPID STORAGE; LIPOGENESIS; LIPOLYSIS; LOCOMOTION; MALE; METABOLIC DISORDER; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE;

ADIPOSE TISSUE; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BODY COMPOSITION; ENERGY METABOLISM; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; LIPOGENESIS; LIPOLYSIS; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; SELF ADMINISTRATION; TIME FACTORS;

EID: 79952702945     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2010.33     Document Type: Article

References (48)

1. Ananth J, Parameswaran S, Gunatilake S. Side effects of atypical antipsychotic drugs. Curr Pharm Des 2004; 10: 2219-2229. (Pubitemid 38832764)
2. Ebenbichler CF, Laimer M, Eder U, Mangweth B, Weiss E, Hofer A et al. Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry 2003; 64: 1436-1439. (Pubitemid 41270101)
3. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001; 62(Suppl 27): 15-26; discussion 40-41. (Pubitemid 34052253)
4. Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004; 65(Suppl 18): 36-46.
5. Newcomer JW. Metabolic risk during antipsychotic treatment. Clin Ther 2004; 26: 1936-1946. (Pubitemid 40353605)
6. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19(Suppl 1): 1-93. (Pubitemid 40677047)
7. Fertig MK, Brooks VG, Shelton PS, English CW. Hyperglycemia associated with olanzapine. J Clin Psychiatry 1998; 59: 687-689.
8. Avella J, Wetli CV, Wilson JC, Katz M, Hahn T. Fatal olanzapineinduced hyperglycemic ketoacidosis. Am J Forensic Med Pathol 2004; 25: 172-175.
9. Torrey EF, Swalwell CI. Fatal olanzapine-induced ketoacidosis. Am J Psychiatry 2003; 160: 2241.
10. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007; 68(Suppl 1): 20-27.
11. Sacher J, Mossaheb N, Spindelegger C, Klein N, Geiss-Granadia T, Sauermann R et al. Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology 2008; 33: 1633-1641. (Pubitemid 351684708)
12. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 2007; 12: 934-945. (Pubitemid 47482696)
13. Vidarsdottir S, de Leeuw van Weenen JE, Frolich M, Roelfsema F, Romijn JA, Pijl H. Effects of olanzapine and haloperidol on the metabolic status of healthy men. J Clin Endocrinol Metab 2010; 95: 118-125.
14. Albaugh VL, Henry CR, Bello NT, Hajnal A, Lynch SL, Halle B et al. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity 2006; 14: 36-51. (Pubitemid 46214773)
15. Arjona AA, Zhang SX, Adamson B, Wurtman RJ. An animal model of antipsychotic-induced weight gain. Behav Brain Res 2004; 152: 121-127. (Pubitemid 38597070)
16. Cooper GD, Pickavance LC, Wilding JP, Halford JC, Goudie AJ. A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl) 2005; 181: 80-89. (Pubitemid 41440918)
17. Goudie AJ, Smith JA, Halford JC. Characterization of olanzapineinduced weight gain in rats. J Psychopharmacol 2002; 16: 291-296. (Pubitemid 35470572)
18. Pouzet B, Mow T, Kreilgaard M, Velschow S. Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav 2003; 75: 133-140. (Pubitemid 36577588)
19. Lee MD, Clifton PG. Meal patterns of free feeding rats treated with clozapine, olanzapine, or haloperidol. Pharmacol Biochem Behav 2002; 71: 147-154. (Pubitemid 34102473)
20. Thornton-Jones Z, Neill JC, Reynolds GP. The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study. J Psychopharmacol 2002; 16: 35-37. (Pubitemid 34273071)
21. Hartfield AW, Moore NA, Clifton PG. Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat. Psychopharmacology (Berl) 2003; 167: 115-122. (Pubitemid 36628151)
22. Benvenga MJ, Leander JD. Increased food consumption by clozapine, but not by olanzapine, in satiated rats. Drug Dev Res 1997; 41: 48-50. (Pubitemid 27490452)
23. Minet-Ringuet J, Even PC, Goubern M, Tome D, Beaurepaire RD. Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. Appetite 2006; 46: 254-262. (Pubitemid 43867820)
24. Cooper GD, Pickavance LC, Wilding JP, Harrold JA, Halford JC, Goudie AJ. Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J Psychopharmacol 2007; 21: 405-413. (Pubitemid 47077303)
25. Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005; 54: 862-871. (Pubitemid 40322092)
26. Shearer J, Coenen KR, Pencek RR, Swift LL, Wasserman DH, Rottman JN. Long chain fatty acid uptake in vivo: comparison of [125I]-BMIPP and [3H]-bromopalmitate. Lipids 2008; 43: 703-711.
27. Robinson AM, Girard JR, Williamson DH. Evidence for a role of insulin in the regulation of lipogenesis in lactating rat mammary gland. Measurements of lipogenesis in vivo and plasma hormone concentrations in response to starvation and refeeding. Biochem J 1978; 176: 343-346. (Pubitemid 9060542)
28. Hajra AK. On extraction of acyl and alkyl dihydroxyacetone phosphate from incubation mixtures. Lipids 1974; 9: 502-505.
29. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-917.
30. Ivy JL, Cortez MY, Chandler RM, Byrne HK, Miller RH. Effects of pyruvate on the metabolism and insulin resistance of obese Zucker rats. Am J Clin Nutr 1994; 59: 331-337. (Pubitemid 24055897)
31. Bergman RN, Hope ID, Yang YJ, Watanabe RM, Meador MA, Youn JH et al. Assessment of insulin sensitivity in vivo: a critical review. Diabetes Metab Rev 1989; 5: 411-429. (Pubitemid 19194684)
32. Crist GH, Xu B, Lanoue KF, Lang CH. Tissue-specific effects of in vivo adenosine receptor blockade on glucose uptake in Zucker rats. FASEB J 1998; 12: 1301-1308. (Pubitemid 28475571)
33. Lang CH, Dobrescu C, Meszaros K. Insulin-mediated glucose uptake by individual tissues during sepsis. Metab: Clin Exp 1990; 39: 1096-1107. (Pubitemid 20351270)
34. Fell MJ, Anjum N, Dickinson K, Marshall KM, Peltola LM, Vickers S et al. The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharmacology (Berl) 2007; 194: 221-231. (Pubitemid 47457949)
35. Caro J, Sinha M, Dohm G, California Uo. Insulin resistance in obesity. In: Bray G, Ricquier D, Spiegelman B (eds). UCLA Symposia on Molecular and Cellular Biology. Wiley-Liss: Keystone, Co, 1989, pp 203-218.
36. Chintoh AF, Mann SW, Lam L, Giacca A, Fletcher P, Nobrega J et al. Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophr Res 2009; 108: 127-133.
37. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. Acute effects of atypical antipsychotics on wholebody insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007; 32: 289-297. (Pubitemid 46106936)
38. Haupt DW, Luber A, Maeda J, Melson AK, Schweiger JA, Newcomer JW. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology 2005; 30: 184-191. (Pubitemid 40024412)
39. Acheson KJ, Schutz Y, Bessard T, Ravussin E, Jequier E, Flatt JP. Nutritional influences on lipogenesis and thermogenesis after a carbohydrate meal. Am J Physiol 1984; 246(1 Pt 1): E62-E70. (Pubitemid 14117095)
40. Chwalibog A, Thorbek G. Energy expenditure by de novo lipogenesis. Br J Nutr 2001; 86: 309. (Pubitemid 32780639)
41. Acheson KJ, Schutz Y, Bessard T, Anantharaman K, Flatt JP, Jequier E. Glycogen storage capacity and de novo lipogenesis during massive carbohydrate overfeeding in man. Am J Clin Nutr 1988; 48: 240-247.
42. Jensen MD, Johnson CM. Contribution of leg and splanchnic free fatty acid (FFA) kinetics to postabsorptive FFA flux in men and women. Metabolism 1996; 45: 662-666. (Pubitemid 26146122)
43. Nelson RH, Basu R, Johnson CM, Rizza RA, Miles JM. Splanchnic spillover of extracellular lipase-generated fatty acids in overweight and obese humans. Diabetes 2007; 56: 2878-2884. (Pubitemid 350223621)
44. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD. Splanchnic lipolysis in human obesity. J Clin Invest 2004; 113: 1582-1588. (Pubitemid 39071681)
45. Minet-Ringuet J, Even PC, Valet P, Carpene C, Visentin V, Prevot D et al. Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Mol Psychiatry 2007; 12: 562-571. (Pubitemid 46816768)
46. Luiken JJ, Dyck DJ, Han XX, Tandon NN, Arumugam Y, Glatz JF et al. Insulin induces the translocation of the fatty acid transporter FAT/CD36 to the plasma membrane. Am J Physiol Endocrinol Metab 2002; 282: E491-E495. (Pubitemid 34654821)
47. Hucking K, Hamilton-Wessler M, Ellmerer M, Bergman RN. Burstlike control of lipolysis by the sympathetic nervous system in vivo. J Clin Invest 2003; 111: 257-264. (Pubitemid 36105925)
48. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 87-96. (Pubitemid 26053226)